161 related articles for article (PubMed ID: 19419927)
1. Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Gautschi O; Mack PC; Davies AM; Jablons DM; Rosell R; Gandara DR
Clin Lung Cancer; 2008; 9 Suppl 3():S129-38. PubMed ID: 19419927
[TBL] [Abstract][Full Text] [Related]
2. A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.
Petty WJ; Knight SN; Mosley L; Lovato J; Capellari J; Tucker R; Blackstock AW; Miller MS; Miller AA
J Thorac Oncol; 2007 Mar; 2(3):197-202. PubMed ID: 17410042
[TBL] [Abstract][Full Text] [Related]
3. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
4. Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720.
Bepler G
Clin Lung Cancer; 2007 Sep; 8(8):509-11. PubMed ID: 17948610
[No Abstract] [Full Text] [Related]
5. Pharmacogenomics and gemcitabine.
Rosell R; Cobo M; Isla D; Camps C; Massuti B
Ann Oncol; 2006 May; 17 Suppl 5():v13-16. PubMed ID: 16807441
[TBL] [Abstract][Full Text] [Related]
6. Impact of biomarkers on non-small cell lung cancer treatment.
Toschi L; Cappuzzo F
Target Oncol; 2010 Mar; 5(1):5-17. PubMed ID: 20443070
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Giovannetti E; Toffalorio F; De Pas T; Peters GJ
Pharmacogenomics; 2012 Jul; 13(9):1073-86. PubMed ID: 22838953
[TBL] [Abstract][Full Text] [Related]
8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
9. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
10. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer.
Rosell R; Manegold C; Moran T; Garrido P; Blanco R; Lianes P; Stahel R; Trigo JM; Wei J; Taron M
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S76-82. PubMed ID: 21885003
[TBL] [Abstract][Full Text] [Related]
11. [Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].
Chen Y; Qian X; Liu B
Zhongguo Fei Ai Za Zhi; 2011 May; 14(5):421-8. PubMed ID: 21569648
[TBL] [Abstract][Full Text] [Related]
12. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T
Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316
[TBL] [Abstract][Full Text] [Related]
13. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
14. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Bepler G; Williams C; Schell MJ; Chen W; Zheng Z; Simon G; Gadgeel S; Zhao X; Schreiber F; Brahmer J; Chiappori A; Tanvetyanon T; Pinder-Schenck M; Gray J; Haura E; Antonia S; Fischer JR
J Clin Oncol; 2013 Jul; 31(19):2404-12. PubMed ID: 23690416
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Fleeman N; Bagust A; McLeod C; Greenhalgh J; Boland A; Dundar Y; Dickson R; Tudur Smith C; Davis H; Green J; Pearson M
Health Technol Assess; 2010 May; 14 Suppl 1():47-53. PubMed ID: 20507803
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Reynolds C; Obasaju C; Schell MJ; Li X; Zheng Z; Boulware D; Caton JR; Demarco LC; O'Rourke MA; Shaw Wright G; Boehm KA; Asmar L; Bromund J; Peng G; Monberg MJ; Bepler G
J Clin Oncol; 2009 Dec; 27(34):5808-15. PubMed ID: 19884554
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
19. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Shimizu J; Horio Y; Osada H; Hida T; Hasegawa Y; Shimokata K; Takahashi T; Sekido Y; Yatabe Y
Respirology; 2008 Jun; 13(4):510-7. PubMed ID: 18494946
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Danesi R; Altavilla G; Giovannetti E; Rosell R
Pharmacogenomics; 2009 Jan; 10(1):69-80. PubMed ID: 19102717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
